Evolution in Cardiovascular Care for Elderly Patients With Non–ST-Segment Elevation Acute Coronary Syndromes

Duke Clinical Research Institute and Division of Cardiology, Duke University Medical Center, Durham, North Carolina 27715, USA.
Journal of the American College of Cardiology (Impact Factor: 15.34). 11/2005; 46(8):1479-87. DOI: 10.1016/j.jacc.2005.05.084
Source: PubMed

ABSTRACT This study evaluated the impact of age on care and outcomes for non-ST-segment elevation acute coronary syndromes (NSTE ACS).
Recent clinical trials have expanded treatment options for NSTE ACS, now reflected in guidelines. Elderly patients are at highest risk, yet have previously been shown to receive less care than younger patients.
In 56,963 patients with NSTE ACS at 443 U.S. hospitals participating in the Can Rapid Risk Stratification of Unstable Angina Patients Suppress Adverse Outcomes With Early Implementation of the American College of Cardiology/American Heart Association Guidelines (CRUSADE) National Quality Improvement Initiative from January 2001 to June 2003, we compared use of guidelines-recommended care across four age groups: <65, 65 to 74, 75 to 84, and > or =85 years. A multivariate model tested for age-related differences in treatments and outcomes after adjusting for patient, provider, and hospital factors.
Of the study population, 35% were > or =75 years old, and 11% were > or =85 years old. Use of acute anti-platelet and anti-thrombin therapy within the first 24 h decreased with age. Elderly patients were also less likely to undergo early catheterization or revascularization. Whereas use of many discharge medications was similar in young and old patients, clopidogrel and lipid-lowering therapy remained less commonly prescribed in elderly patients. In-hospital mortality and complication rates increased with advancing age, but those receiving more recommended therapies had lower mortality even after adjustment than those who did not.
Age impacts use of guidelines-recommended care for newer agents and early in-hospital care. Further improvements in outcomes for elderly patients by optimizing the safe and early use of therapies are likely.

Download full-text


Available from: William E Boden, Jan 02, 2014
  • [Show abstract] [Hide abstract]
    ABSTRACT: The American College of Cardiology and American Heart Association publishes evidence-based guideline recommendations, yet the degree to which these guidelines are followed and the association between hospital guideline adherence and patient outcomes are unknown. Using data from 350 US centers participating in the "Can Rapid Risk Stratification of Unstable Angina Patients Suppress Adverse Outcomes With Early Implementation of the American College of Cardiology/American Heart Association Guidelines" Quality Improvement Initiative, we evaluated the in-hospital treatment and outcomes from 64,775 patients with non-ST-segment elevation acute coronary syndromes. Overall, guideline-recommended treatments were followed in 74% of eligible instances. However, hospitals varied considerably in their composite adherence rates (median lowest to highest adherence hospital quartiles 63% to 82%). We also noted significant age, gender, and racial disparities in the use of guideline-recommended therapies as well as significant facility type and regional variability in care. Composite guideline adherence rates were significantly associated with in-hospital mortality. After risk adjustment, every 10% increase in composite adherence at a hospital was associated with a 10% reduction in its patients' likelihood of in-hospital mortality. Our findings support the use of broad, guideline-based performance metrics as a means of assessing and helping improve hospital quality.
    The Journal of cardiovascular nursing 01/2008; 23(1):50-5. DOI:10.1097/01.JCN.0000305058.03872.f1 · 1.81 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The care of elderly patients with non-ST-elevation acute coronary syndrome is challenging, given the wide variability in physiologic condition and preferences among this patient group. Due to a higher burden of comorbidity, the elderly face high risks for death and complications from non-ST-elevation acute coronary syndrome relative to younger patients. Accordingly, they also have greater potential benefits from effective therapies. Antithrombotic therapy, invasive cardiac care, lipid lowering, and prevention advice, however, are all used less often in the elderly, even when no contraindications exist. Attention to individualized dosing and safety monitoring is also important for elderly patients. Increased awareness of the beneficial impact of therapies on outcomes in the elderly, along with vigilance for adverse events, should enable care to move from the state of uncertainty to opportunity in this high-risk population.
    The American Journal of Geriatric Cardiology 01/2006; 15(1):42-9. DOI:10.1111/j.1076-7460.2006.04642.x · 0.86 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Adults over the age of 65years represent more than half of the patients living with heart disease in the United States. However, the majority of the large, multi-center, randomized clinical trials that have led to the creation of the guidelines for antiplatelet therapy have enrolled only a small number of elderly patients. This article reviews the published data on antiplatelet therapy for coronary artery and cerebrovascular disease, focusing on elderly patients. We found evidence to support the use of aspirin for both primary and secondary prevention of ischemic heart disease, and of aspirin and clopidogrel in the setting of acute coronary syndromes and for stroke prevention in patients with atrial fibrillation not on anticoagulation. Further studies are needed to characterize the benefits and risks in the elderly of prasugrel, ticagrelor and the glycoprotein IIb/IIIa inhibitors. KeywordsAntiplatelet–Ischemic heart disease–Age–Elderly–Aspirin–Clopidogrel–Prasugrel–Ticagrelor
    Current Cardiovascular Risk Reports 01/2011; 5(1):86-95. DOI:10.1007/s12170-010-0134-4